Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification-Reference-Cited by-同舟云学术

Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification

Published:2024-01-30 Issue:2 Volume:14 Page:200
ISSN:2075-1729
Container-title:Life
language:en
Short-container-title:Life

Author:

Alajmi Fahad¹,Kang Mehima¹,Dundas James²³,Haenel Alexander¹,Parker Jeremy¹,Blanke Philipp¹²,Coghlan Fionn¹,Khoo John King¹,Bin Zaid Abdulaziz A.¹,Singh Amrit⁴,Heydari Bobby¹,Yeung Darwin¹,Roston Thomas M.¹,Ong Kevin¹,Leipsic Jonathon²,Laksman Zachary¹

Affiliation:

1. Center for Cardiovascular Innovation, Division of Cardiology, Department of Medicine, University of British Columbia, 2775 Laurel St, 9th Floor, Vancouver, BC V5Z 1M9, Canada

2. Department of Radiology, University of British Columbia, 2775 Laurel Street, 11th Floor, Vancouver, BC V5Z 1M9, Canada

3. Department of Cardiology, North Tees and Hartlepool NHS Foundation Trust, Hardwick Rd, Hardwick, Stockton-on-Tees TS19 8PE, UK

4. Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Medical Sciences, 2176 Health Sciences Mall Block C217, Vancouver, BC V6T 2A1, Canada

Abstract

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder with a well described risk of sudden cardiac death; however, risk stratification has remained a challenge. Recently, novel parameters in cardiac magnetic resonance imaging (CMR) have shown promise in helping to improve upon current risk stratification paradigms. In this manuscript, we have reviewed novel CMR risk markers and their utility in HCM. The results of the review showed that T1, extracellular volume, CMR feature tracking, and other miscellaneous novel CMR variables have the potential to improve sudden death risk stratification and may have additional roles in diagnosis and prognosis. The strengths and weaknesses of these imaging techniques, and their potential utility and implementation in HCM risk stratification are discussed.

Funder

Genome British Columbia Data Access, Integration and Analysis Program

St. Paul’s Hospital Foundation

Publisher

MDPI AG

Link

https://www.mdpi.com/2075-1729/14/2/200/pdf

Reference44 articles.

1. Hypertrophic cardiomyopathy: An updated review on diagnosis, prognosis, and treatment;Makavos;Heart Fail. Rev.,2019

2. 2023 ESC Guidelines for the management of cardiomyopathies;Arbelo;Eur. Heart J.,2023

3. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death;Zeppenfeld;Eur. Heart J.,2022

4. Sudden Cardiac Death: Who Is at Risk?;Jazayeri;Med. Clin. N. Am.,2019

5. Writing Committee Members, Ommen, S.R., Mital, S., Burke, M.A., Day, S.M., Deswal, A., Elliott, P., Evanovich, L.L., Hung, J., and Joglar, J.A. (2020). Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Circulation, 142, E558–E631. Available online: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000937.